Advaxis Announces Agreement with Columbia University Irving Medical Center to Fund Phase 1 Study of ADXS-504 for the Treatment of Early Prostate Cancer Nasdaq:ADXS

Advaxis Announces Agreement with Columbia University Irving Medical Center to Fund Phase 1 Study of ADXS-504 for the Treatment of Early Prostate Cancer Nasdaq:ADXS

News Highlights

PRINCETON, N.J., April 05, 2021 (News) — Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced an agreement with Columbia University Irving Medical Center to fund a Phase 1 clinical study evaluating ADXS-504 in patients with biochemically recurrent prostate cancer. The study, expected to begin in Q2 2021, will be the first clinical evaluation of ADXS-504, Advaxis’ off-the-shelf neoantigen immunotherapy drug candidate for early prostate cancer. Mark Stein, M.D., associate professor of medicine in the Division of Hematology/Oncology at Columbia University Vagelos College of Physicians and Surgeons, will be the study’s principal investigator.

The Phase 1 open-label study will evaluate the safety and tolerability of ADXS-504 monotherapy, administered via infusion, in 9-18 patients with biochemically recurrent prostate cancer, i.e., those with elevation of prostate-specific antigen (PSA) in the blood after radical prostatectomy or radical radiotherapy (external beam or brachytherapy) and who are not currently receiving androgen ablation therapy. The study will also evaluate preliminary clinical and immune responses following treatment with ADXS-504 monotherapy.

Nearly 248,530 men in the United States will be diagnosed with prostate cancer in 2021, and approximately 34,130 will die from this disease. Many more men with prostate cancer will experience rising prostate-specific antigen (PSA) levels following local therapy with radical radiotherapy or prostatectomy, a condition known as biochemical recurrence (BCR). BCR is not typically associated with imminent death, and biochemical progression may occur over a prolonged period. Clinicians treating men with BCR thus face a difficult set of decisions in attempting to delay the onset of metastatic disease and death while avoiding over-treating patients whose disease may never affect their overall survival or quality of life.

“Currently, men with biochemically recurrent prostate cancer are either monitored for a period of time without intervention or may be started on medicine to decrease the level of testosterone in the body, which can have significant side effects,” said Dr. Stein. “Therefore, we need new approaches to stimulate the body’s immune system to control the prostate cancer. Given the encouraging results from a Phase 2 study of ADXS-PSA, which targets a single-antigen, in combination with KEYTRUDA®, in men with advanced prostate cancer, and emerging signals of potential clinical activity of the Company’s multi-antigen technology in non-small cell lung cancer, we are excited to have the opportunity to explore the potential of ADXS-504 immunotherapy as a novel treatment modality for biochemically recurrent prostate cancer.”

ADXS-504 is a novel Lm-based immunotherapy, bioengineered to elicit T cell responses against 24 tumor antigens that include 14 peptide antigens derived from frequently occurring and commonly shared hotspot mutations in patients with prostate cancer and 10 peptide antigens derived from sequence-optimized tumor-associated antigens (TAAs) that are differentially expressed or overexpressed in prostate cancer. ADXS-504 is designed to express multiple tumor antigen targets to which patients may generate a broad set of effector T cells for tumor control. Similar to Advaxis’ other Lm-based immunotherapies, ADXS-504 is expected to induce an innate immune response followed by the adaptive response and modification of the immunosuppressive tumor microenvironment (TME) by reducing regulatory T cells (Tregs) and myeloid-derived suppressor cell (MDSC) frequencies in the TME.

Kenneth A. Berlin, President and Chief Executive Officer of Advaxis said, “We are pleased to be working with Columbia University Irving Medical Center to conduct the first clinical evaluation of ADXS-504 in earlier stages of prostate cancer where drug constructs of this type could potentially control micrometastasis efficiently. The strategic decision to transition the ADXS-504 to an investigator-sponsored study at Columbia will provide access to world-class expertise and has the potential to accelerate patient recruitment in order to expedite our clinical progress. We are encouraged by our momentum and look forward to continued progress across our ADXS-HOT program, which also includes ongoing studies in NSCLC in the first line setting and in patients who have progressed on pembrolizumab.”

About Advaxis

Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.

Forward Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are any statements that express the current beliefs and expectations of management. Any statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. Such risks include, but are not limited to: the success and timing of the Company’s clinical trials, including patient accrual; the Company’s ability to develop and commercialize its products; the Company’s ability to identify license and collaboration partners and to maintain existing relationships; the Company’s available cash and its ability to obtain additional funding; and any outcomes from the Company’s review of strategic transactions. These and other risks are discussed in the Company’s filings with the SEC, including, without limitation, its Annual Report on Form 10-K, filed on December 20, 2019, as amended, and its periodic reports on Form 10-Q and Form 8-K. The Company cautions readers not to place undue reliance on any forward-looking statements, which speak only as of the date they were made. The Company undertakes no obligation to update or revise forward-looking statements whether as a result of new information, future events or otherwise, except as otherwise required by law.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA.

Contact:Tim McCarthy, LifeSci Advisors, LLC212.915.2564tim@lifesciadvisors.com

  • Check the latest Health news updates and information.
  • Please share this news Advaxis Announces Agreement with Columbia University Irving Medical Center to Fund Phase 1 Study of ADXS-504 for the Treatment of Early Prostate Cancer Nasdaq:ADXS with your friends and family to support us your one share helps us a lot.
Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more

For Latest News Follow us on Google News


Latest Headlines
  • Show all
  • Trending News
  • Popular By week
Resident Evil 4 VR announced for Oculus Quest 2 as a first-person remake

Resident Evil 4 VR announced for Oculus Quest 2 as a first-person remake

Stare down the abyss with weaponry at the ready. Another angle of knifey-gunney. ...
Bitcoin drops to $ 52,000 with $ 7.6 billion in encrypted long positions

Bitcoin drops to $ 52,000 with $ 7.6 billion in encrypted long positions

Source www.theblockcrypto.com Related Reading Overall, $9.2 billion in crypto long positions have been liquidated in the last 24 hours.  As of the time of ...
Scottish brewer BrewDog chooses The Avian on the Scranton Peninsula for lease in Cleveland

Scottish brewer BrewDog chooses The Avian on the Scranton Peninsula for lease in Cleveland

BrewDog plans to use the back of the property for a large outdoor space along the water with views of downtown. Surface-id Ltd. “People’s desire to go ...
Wall Street stocks end the week at record highs

Wall Street stocks end the week at record highs

This sense of economic enthusiasm sparked a heavy retreat in long-term US government bonds during the first quarter of this year. However, the direction of ...
Hilo man accused of stealing 2 Hilo business

Hilo man accused of stealing 2 Hilo business

Charges stem from business thefts that occurred on April 14. Pili remains in custody in lieu of $57,000 bail. “Today’s charges reflect Hawai‘i Island law ...
Alarming Probiotic Weight Loss Scam Exposed!

Alarming Probiotic Weight Loss Scam Exposed!

News HighlightsMadison, WI, April 17, 2021 (News) — The majority of people in America today have been overweight at some point in their lives. Millions ...
Xbox Live Gold makes new games free for subscribers

Xbox Live Gold makes new games free for subscribers

Availability: Free Until May 15 Platform: Xbox One prevnextTruck Racing Championship About: “The only official simulation that features all the unique ...
Sustaining maternal and child health – United Republic of Tanzania

Sustaining maternal and child health – United Republic of Tanzania

Source “SUSTAIN’s support has been crucial, because it has changed the community and us as practioners, because we are now many and we do operations here, and ...
We cannot allow the state government to take more money out of our wallets |  News, sports, jobs

We cannot allow the state government to take more money out of our wallets | News, sports, jobs

One environmental lobbyist had the nerve to suggest that fossil fuel companies may not pass the gas tax on to consumers and instead choose to cut executive ...
Secretary of State warns of misleading business direct mail

3 stocks with big dividends, whose payments could double | Smart change: personal finance

It’s unlikely that the chain will achieve that rate of growth again in the next few years, but it should still thrive as the pandemic’s influence declines ...
Show next
Compsmag - Latest News from tech, business and health
Logo